328 W. Claiborne St.
P.O. Box 964
Monroeville, Alabama 36460
(251) 575-4203
     
Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Could Herpes Virus Play a Role in Alzheimer's?Health Tip: Living With Dementia"Markers" of Alzheimers Do Not Doom You to DementiaMaking Life With Dementia More BearableWhen Do You Take Guns From Someone With Dementia?Mild TBI Linked to Increased Dementia Risk in VeteransEven Mild Concussion Tied to Greater Dementia Risk Later'Smart Dresser' Might Help Alzheimer's Patients Clothe ThemselvesMusic May Calm the Agitation of Alzheimer'sRural Childhood, Higher Education Cuts Later Life Dementia RiskControlling High Blood Pressure Could Prevent DementiaAnnual Visits May Not Increase Cognitive Impairment DetectionMild TBI May Increase Risk of Parkinson's DiseaseBrain Injuries Linked With Dementia RiskThe Focus Shifts in Alzheimer's ResearchSleepless Nights Show Ties To Alzheimer's RiskMontreal Parkinson Risk of Dementia Scale Deemed AccurateNurse Education Improves Post-Op Survival in Dementia PatientsAlzheimer's Stigma a Barrier to Prevention, Care: SurveyConcern for Employer, Insurance Discrimination for Alzheimer's PatientsScientists Remove Alzheimer's Brain Plaques in MiceThe High Costs of Alzheimer'sPoor Sleep May Heighten Alzheimer's RiskWhat Caregivers Should Know About Alzheimer'sHealth Tip: Recognize Symptoms of Traumatic Brain InjuryHealth Tip: Next Steps After Being Diagnosed With Alzheimer'sEyes May Be Window Into Future Memory LossCardiorespiratory Fitness, White Matter Integrity Tied to CognitionMolecular Markers May ID Alzheimer's Before Clinical OnsetIn Alzheimer's, BACE1 Inhibition May Reverse Amyloid DepositionTherapy Reverses Alzheimer's Brain Plaque Buildup -- in MiceLow Serum Sodium Linked to Cognitive Decline in Older MenPositive Age Beliefs May Protect Seniors Against DementiaYour Attitude About Aging Might Affect Odds for DementiaWhat Works Best to Keep Drivers With Dementia Off the RoadDeep Brain Stimulation May Be Promising Alzheimer's TreatmentEarly Alzheimer's Tied to Rest-Activity Rhythm FragmentationBrain 'Pacemaker' Might Help Slow Alzheimer'sSolanezumab Doesn't Affect Cognitive Decline in Alzheimer'sAnother Alzheimer's Drug Fails: What Makes This Disease So Tough to Fight?Seizure Drug May Help Ease Symptoms of Major Form of DementiaHealth Tip: Disaster Preparedness For People With Alzheimer'sFalls More Common in Elderly With Cognitive ImpairmentConcussion May Not Be Needed to Bring on CTE Brain DiseaseAlzheimer's Disease Variants Linked to Brain AmyloidosisIdalopirdine May Not Improve Cognition in Mild Alzheimer'sHealth Tip: Alzheimer's and the HolidaysNo Magic Bullet for Preventing Late-Life DementiaDementia May Be More Common in Rural AreasThere's Still No Proven Way to Prevent Alzheimer's
Links
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Idalopirdine May Not Improve Cognition in Mild Alzheimer's


HealthDay News
Updated: Jan 9th 2018

new article illustration

TUESDAY, Jan. 9, 2018 (HealthDay News) -- The use of idalopirdine does not improve cognition versus placebo over 24 weeks of treatment for patients with mild-to-moderate Alzheimer's disease (AD), according to research published in the Jan. 9 issue of the Journal of the American Medical Association.

Alireza Atri, M.D., Ph.D., from the California Pacific Medical Center in San Francisco, and colleagues conducted three randomized 24-week clinical trials that included 2,525 patients aged 50 years or older with mild-to-moderate AD to examine whether idalopirdine is effective for symptomatic treatment of mild-to-moderate AD.

The researchers found that the mean change in the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) was 0.37, 0.61, and 0.41 for the 60- and 30-mg idalopirdine groups and the placebo group, respectively (adjusted mean difference versus placebo: 0.05 [95 percent confidence interval (CI), −0.88 to 0.98] and 0.33 [95 percent CI, −0.59 to 1.26], respectively), in study 1. In study 2, the mean change in ADAS-Cog total score was 1.01, 0.53, and 0.56 for the 30- and 10-mg groups, and placebo, respectively (adjusted mean difference versus placebo, 0.63 [95 percent CI, −0.38 to 1.65] for the 30-mg group). The mean change in ADAS-Cog total score in study 3 was 0.38 and 0.82 for the 60-mg and placebo groups, respectively (adjusted mean difference, −0.55 [95 percent CI, −1.45 to 0.36]).

"These findings do not support the use of idalopirdine for the treatment of AD," the authors write.

Several authors disclosed financial ties to medical device and pharmaceutical companies, including H. Lundbeck A/S, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net